Healthcare Industry News: cannabinoids
News Release - January 5, 2021
Enveric Biosciences Appoints Dr. Marcus Schabacker to Board of DirectorsIndustry Veteran Brings Over Three Decades of Experience Across Global Healthcare Landscape
NAPLES, Fla., Jan. 5, 2021 -- (Healthcare Sales & Marketing Network) -- Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, announced today that it has appointed Marcus Schabacker, M.D., Ph.D., to the Company's Board of Directors.
With more than 35 years of healthcare experience, Dr. Schabacker currently serves as President and CEO at the ECRI Institute, a nonprofit organization focused on advancing effective, evidence-based healthcare globally. Prior to joining ECRI, Dr. Schabacker worked at Baxter Healthcare Corporation, serving in various roles including Corporate Vice President and Chief Scientific Officer; Chairman of the Executive Quality Council; Chief Scientific Officer, Medical Products; and Vice President, R&D, Medical Products.
For over a decade, Dr. Schabacker has served on numerous boards of both small- and mid-sized companies, providing organizations with strategic guidance for accelerating growth and building successful, sustainable management teams. He is also a board-certified anesthesiologist and intensive care specialist.
"Over the course of my career, and still to this day, patients' needs remain my top priority," added Dr. Schabacker. "The team at Enveric Biosciences lives by this principle, as well, which is why I could not pass up the opportunity to join its Board of Directors. As the Company advances its pipeline of innovative, naturally occurring compounds in partnership with leading clinics, I look forward to working closely with Enveric to help bring these treatments to patients in need, especially those suffering from cancer treatments' debilitating side effects."
About Enveric Biosciences Enveric Biosciences is a patient-first biotechnology company developing rigorously tested, novel cannabinoid medicines to improve quality of life for cancer patients. Initial indications include radiodermatitis, a common and often severe side effect of radiation therapy, and chemotherapy-induced neuropathy. For more information, please visit https://www.enveric.com/.
This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as "plans", " expects" or "does not expect", "proposed", "is expected", "budgets", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the Amalgamation will be consummated or that the parties other plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific that contribute to the possibility that the predictions, estimates, forecasts, projections and other forward-looking statements will not occur.
The forward-looking statements contained in this press release are made as of the date of this press release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made by, third parties in respect of the matters discussed above.
Source: Enveric Biosciences
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.